Tesaro CEO Says Its Drug 'Will Get There' — Analysts Strongly Disagree

Tesaro CEO Says Its Drug 'Will Get There' — Analysts Strongly Disagree

Source: 
Investors.com
snippet: 

Tesaro (TSRO) stock crashed to a four-year low Friday after the biotech cut its 2018 outlook and analysts suggested its key drug, Zejula, is struggling to gain traction in the U.S.